Pattern of failures and clinical outcome of patients with locally advanced cervical cancer treated with a tailored integrated therapeutic approach

Anticancer Research

Volumn 30, Issue 9, 2010, Pages 3731-3735

  Gadducci, Angiolo ^a   Fabrini, Maria Grazia ^a   Perrone, Franco ^b   Manfredi, Bruno ^a   Fanucchi, Antonio ^a   Laliscia, Concetta ^a   Barsotti, Cecilia ^a   Scotti, Valerio ^a   Genazzani, Andrea Riccardo ^a   Greco, Carlo ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Brachytherapy; Cervical cancer; Chemoradiotherapy; Neoadjuvant chemotherapy; Radical hysterectomy

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IFOSFAMIDE; MESNA; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; BRACHYTHERAPY; CANCER STAGING; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG TREATMENT FAILURE; FEMALE; HEMORRHAGIC CYSTITIS; HUMAN; HUMAN TISSUE; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROCTITIS; RADICAL HYSTERECTOMY; RECTUM DISEASE; RECTUM STENOSIS; REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URETER FISTULA; URETER OBSTRUCTION; UTERINE CERVIX CANCER; ADJUVANT THERAPY; HYSTERECTOMY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; RADIOTHERAPY; RETROSPECTIVE STUDY; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; HYSTERECTOMY; IFOSFAMIDE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; PACLITAXEL; RADIOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 77958588100     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG: Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 340: 1137-1143, 1999.
2. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL 3rd, Walker JL and Gersell D: Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340: 1154-1161, 1999.
3. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr., Clarke-Pearson DL and Liao SY: Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 17: 1339-1348, 1999.
4. Peters WA 3rd, Liu PY, Barrett RJ 2nd, Stock RJ, Monk BJ, Berek JS, Souhami L, Grigsby P, Gordon W Jr. and Alberts DS: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 18: 1606-1613, 2000.
5. Rose PG: Chemoradiotherapy: the new standard care for invasive cervical cancer. Drugs 60: 1239-1244, 2000. (Pubitemid 32039384)
6. Rose PG: Chemoradiotherapy for cervical cancer Eur J Cancer 38: 270-278, 2002.
7. Rose PG, Ali S, Watkins E, Thigpen JT, Deppe G, Clarke-Pearson DL, Insalaco S; Gynecologic Oncology Group: Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol 25: 2804-2810, 2007.
8. Chemoradiotherapy for Cervical Cancer Meta-analysis Collaboration (CCCMAC): Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. Cochrane Database of Systematic Reviews 1: CD008285, 2010.
9. Sardi JE, Giaroli A, Sananes C, Ferreira M, Soderini A, Bermudez A, Snaidas L, Vighi S, Gomez Rueda N and di Paola G: Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 67: 61-69, 1997.
10. Benedetti-Panici P, Greggi S, Colombo A, Amoroso M, Smaniotto D, Giannarelli D, Amunni G, Raspagliesi F, Zola P, Mangioni C and Landoni F: Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. J Clin Oncol 20: 179-188, 2002.
11. Rydzewska L, Tiemey J, Vale CL and Symonds PR: Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 1: CD007406, 2010.
12. Buda A, Fossati R, Colombo N, Fei F, Floriani I, Gueli Alletti D, Katsaros D, Landoni F, Lissoni A, Malzoni C, Sartori E, Scollo P, Torri V, Zola P and Mangioni C: Randomized trial of neoadjuvant chemotherapy comparing paclitaxel, ifosfamide, and cisplatin with ifosfamide and cisplatin followed by radical surgery in patients with locally advanced squamous cell cervical carcinoma: the SNAP01 (Studio Neoadjuvante Portio) Italian Collaborative Study. J Clin Oncol 23: 4137-4145, 2005.
13. González-Martín A, González-Cortijo L, Carballo N, Garcia JF, Lapuente F, Rojo A and Chiva LM: The current role of neoadjuvant chemotherapy in the management of cervical carcinoma. Gynecol Oncol 110(5 Suppl 2): S36-40, 2008.
14. Cho YH, Kim DY, Kim JH, Kim YM, Kim YT and Nam JH: Comparative study of neoadjuvant chemotherapy before radical hysterectomy and radical surgery alone in stage IB2-IIA bulky cervical cancer. J Gynecol Oncol 20: 22-27, 2009.
15. Quinn MA, Benedet JL, Odicino F, Maisonneuve P, Beller U, Creasman WT, Heintz AP, Ngan HY and Pecorelli S: Carcinoma of the cervix uteri. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynecol Obstet 95(Suppl 1): S43-103, 2006.
16. International Commission on Radiation Units and Measurements Report 38: Dose and Volume Specifications for Reporting Intracavitary Therapy in Gynecology. International Commission in Radiation Units and Measurements, Bethesda MD, pp. 1-23, 1985.
17. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D and Verweij J: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45: 228-247, 2009.
18. Gadducci A, Teti G, Barsotti C, Tana R, Fanucchi A, Orlandini C, Fabrini MG and Genazzani AR: Clinicopathological variables predictive of clinical outcome in patients with FIGO stage Ib2-IIb cervical cancer treated with cisplatin-based neoadjuvant chemotherapy followed by radical hysterectomy. Anticancer Res 30: 201-208, 2010.
19. Kim DS, Moon H, Kim KT, Hwang YY, Cho SH and Kim SR: Two-year survival: preoperative adjuvant chemotherapy in the treatment of cervical cancer stages Ib and II with bulky tumor. Gynecol Oncol 33: 225-230, 1989. (Pubitemid 19112919)
20. Giaroli A, Sananes C, Sardi JE, Maya AG, Bastardas ML, Snaidas L, Rueda NG, Vighi S and di Paola GR: Lymph node metastases in carcinoma of the cervix uteri: response to neoadjuvant chemotherapy and its impact on survival. Gynecol Oncol 39: 34-39, 1990. (Pubitemid 20378256)
21. Colombo N, Gabriele A, Lissoni A, Vecchione F, Zanetta G, Pellegrino A, Maneo A, Floriani I and Landoni F: Neoadjuvant chemotherapy (NACT) in locally advanced uterine cervical cancer (LAUCC): Correlation between pathological response and survival. Proc Am Soc Clin Oncol 17: 352a, (abstr 1359), 1998.